

























































































































































































































patients with acute heart
failure: the RELAHF study
Introduction
Relaxin is a natural hormone of the insulin
family which is detected only at very low
blood concentrations (<10 pg/mL) in a small
proportion of healthy people (<20%), with
the exception of pregnant women, in whom
blood concentrations usually increase to
over 100 times the baseline concentration
(>1000 pg/mL).1–3 Relaxin plays a role in the
regulation of vascular tone by binding to the
RXFP1 receptors present in the renal and
systemic vasculature.4
In the recent RELAX-AHF (RELAXin in
Acute Heart Failure) clinical trial, serelaxin,
a recombinant form of relaxin, was admin-
istered to patients with acute heart failure
(AHF), resulting in an improvement in dys-
pnoea and a possible increase in mid-term
survival.5 However, the mechanism behind
these beneficial results is not completely
understood. A few studies have reported
that relaxin concentrations are elevated
in patients with moderate–severe dilated
cardiomyopathy and are correlated with the
severity of heart failure (HF),6 but not with
mortality or rehospitalization rates or with
natriuretic peptide blood concentrations.
In a recent study, relaxin concentrations
were found to be related to clinical and
echocardiographic markers of pulmonary
hypertension.7
In view of the scarcity of data, we designed
the present exploratory study in patients with
AHF recruited in emergency departments
(EDs). The objectives were to investigate: (i)
the frequencies of patients with detectable
and undetectable relaxin concentrations; (ii)
the clinical factors associated with unde-
tectable relaxin concentrations and whether
undetectable relaxin concentrations are
associated with short-term outcome, and (iii)
the clinical factors associated with relaxin
concentrations in patients with detectable
values and whether there is a relation-
ship between relaxin concentrations and
short-term outcome.
Methods
The RELAHF (RELaxine blood concentrations
in patients with Acute Heart Failure) study
was designed as a prospective, analytical,
observational, multicentre study with cohort
follow-up to analyse human relaxin-2 con-
centrations in consecutive patients diagnosed
with AHF in four Spanish EDs over 2 months
(January and February 2014). The diagnostic
criteria for AHF were those defined by the
guidelines of the European Society of Cardi-
ology prevailing at the time of the study.8 The
criteria for patient inclusion were identical to
those in previous studies conducted by our
research group.9 Blood samples were taken
at the time of the first investigation in the
ED and were stored at −80∘C until transfer
to the reference laboratory for processing.
The study was approved by the committees
for ethics and clinical investigation of the
participating hospitals and was developed
according to the Declaration of Helsinki.
Clinical variables
We collected data on these variables: demo-
graphic characteristics; co-morbidities;
baseline functional and cardiorespiratory
status [Barthel index and New York Heart
Association (NYHA) class, respectively];
chronic treatment, and vital signs (electro-
cardiographic and analytical data) on arrival
at the ED. Lastly, echocardiographic data for
the 6 months prior to the current ED index
episode were collected.
Follow-up and events
Follow-up was carried out by telephone and
referred to clinical history noted in both
hospital and primary care contexts, as well as
local death registries. The primary event was
30-day all-cause death.
Biochemical analyses
N-terminal pro-brain natriuretic peptide (NT-
proBNP) and relaxin-2 concentrations were
determined in a central laboratory blinded
to clinical details. Extraction and storage
conditions for the transportation of samples
were predefined and standardized across all
sites. Relaxin-2 quantification was performed
using the enzyme-linked immunosorbent
assay (ELISA) sandwich method using two
polyclonal antibodies able to bind to human
relaxin (Immundiagnostik AG, Bensheim,
Germany) in an automated Triturus system
(Grifols SA, Barcelona, Spain). The detection
limit was 1.5 pg/mL, and the range of linearity
was set at 1.5–250 pg/mL. Levels of inter- and
intra-assay inaccuracy were less than 8%. As
this is not a standardized technique, duplicate
determinations were carried out in 20% of
the samples to confirm the correlation.
Data collection and statistical
analyses
Categorical variables are expressed as the
number and percentage, and quantitative
variables as the mean and standard deviation
[or median and interquartile range (IQR)
if not normally distributed]. Patients were
dichotomized based on whether relaxin-2
levels were detectable or not. Patients with
detectable concentrations were grouped by
quartiles. Categorical variables were com-
pared with the 𝜒2 test or Fisher’s exact
test. Quantitative variables were compared
by analysis of variance (ANOVA) (or the
Kruskal–Wallis non-parametric test if not
normally distributed). Correlations among
biomarkers were measured by linear regres-
sion. Survival analysis was carried out using
the Cox proportional hazard method with
30-day curves; crude hazard ratios (HRs)
with 95% confidence intervals (CIs) were
calculated and adjusted for differences among
the groups found in the univariate study. An
interaction analysis was predefined for sex,
age and type of AHF (first episode of AHF vs.
decompensation of known chronic HF).
Results
The cohort included 522 patients. Relaxin-2
concentrations were undetectable (<1.5
pg/mL) in 92 (17.6%) subjects, more fre-
quently in men (P< 0.001) and those treated
with aldosterone receptor antagonists
(P= 0.03) (Table 1). Thirty-day mortality in
patients with undetectable relaxin-2 con-
centrations was significantly lower than in
those with detectable concentrations (2.2%
© 2017 The Authors








































































































































































































































Table 1 Baseline characteristics of the study population and comparisons between patients with undetectable








. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sociodemographic variables
Age, years, mean ± SD 80.9 ± 9.1 80.68 ± 9.58 80.95 ± 8.95 0.79
Female sex, n (%) 280 (53.6%) 34 (37.0%) 246 (57.2%) <0.001
Co-morbidity, n (%)
Arterial hypertension 431 (82.6%) 74 (80.4%) 357 (83.0%) 0.55
Diabetes mellitus 204 (39.1%) 35 (38.0%) 169 (39.3%) 0.82
Dyslipaemia 203 (38.9%) 37 (40.2%) 166 (38.6%) 0.77
Ischaemic heart disease 170 (32.6%) 31 (33.7%) 139 (32.3%) 0.80
Heart valve disease 116 (22.2%) 12 (13.0%) 104 (24.2%) 0.02
Atrial fibrillation 264 (50.6%) 46 (50.0%) 218 (50.7%) 0.90
Chronic kidney disease 140 (26.8%) 25 (27.2%) 115 (26.8%) 0.94
Cerebrovascular disease 67 (12.8%) 11 (12.0%) 56 (13.0%) 0.78
COPD 105 (20.1%) 18 (19.6%) 87 (20.2%) 0.89
Peripheral artery disease 44 (8.4%) 9 (9.8%) 35 (8.2%) 0.61
First episode of HF 207 (39.7%) 37 (40.2%) 170 (39.5%) 0.96
Basal status, n (%)
Basal NYHA III or IV 93 (17.8%) 19 (20.6%) 74 (17.2%) 0.39
Barthel Index <60 pointsb 59 (12.2%) 11 (13.1%) 48 (12.0%) 0.77
Type of ventricular dysfunctionb, n (%)
Systolic 103 (19.7%) 23 (54.8%) 80 (48.2%) 0.45
Diastolic 105 (20.1%) 19 (45.2%) 86 (51.8%)
Known LVEF 208 (39.8%) 42 (45.7%) 166 (38.6%) 0.21
Chronic treatment, n (%)
Loop diuretics 334 (64.0%) 60 (65.2%) 274 (63.7%) 0.79
Potassium-sparing diuretics 85 (16.3%) 22 (23.9%) 63 (14.7%) 0.03
Thiazide diuretics 55 (10.5%) 10 (10.9%) 45 (10.5%) 0.91
Beta-blockers 184 (35.2%) 34 (37.0%) 150 (34.9%) 0.71
ACE inhibitors 136 (26.1%) 22 (23.9%) 114 (26.5%) 0.61
ARB II 121 (23.2%) 19 (20.7%) 102 (23.7%) 0.53
Nitrates 88 (16.9%) 11 (12.0%) 77 (17.9%) 0.17
Digoxin 79 (15.1%) 11 (12.0%) 68 (15.8%) 0.35
Clinical data for the acute episode
Heart rate, b.p.m., mean ± SD 90.2 ± 26.0 87.7 ± 22.6 90.7 ± 26.7 0.33
Respiratory rate, breaths/min, mean ± SD 23.7 ± 8.3 22.3 ± 7.3 23.9 ± 8.5 0.16
SBP, mmHg, mean ± SD 142.7 ± 26.4 140.8 ± 27.9 143.1 ± 26.1 0.45
SaO2 <90%, n (%) 129 (24.7%) 24 (26.7%) 105 (24.4%) 0.77
Electrocardiogram, n (%)
Atrial fibrillation in the ECG 261 (50.0%) 47 (51.1%) 214 (49.8%) 0.82
LBBB/pacemaker 83 (15.9%) 12 (13.0%) 71 (16.5%) 0.42
Left ventricular hypertrophy 17 (3.3%) 2 (2.2%) 15 (3.5%) 0.52
Laboratory tests, n (%)
Anaemia 292 (55.9%) 53 (57.6%) 239 (55.6%) 0.72
eGFR <60 mL/min/1.73 m2 305 (58.4%) 58 (63.0%) 247 (57.4%) 0.32
Sodium <135 mEq/L 108 (20.7%) 19 (20.7%) 89 (20.7%) 0.99
Potassium 3.5–5.0 mEq/L 397 (76.1%) 75 (81.5%) 322 (74.9%) 0.41
Normalized troponins, mean ± SD 3.79 ± 8.0 4.97 ± 12.9 3.53 ± 6.5 0.34
NT-proBNP, pmol/L (median p25–p75) 4160 (1751–9132) 3896 (1737–7446) 4219 (1774–9345) 0.45
ACE, angiotensin-converting enzyme; ARB II, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; eGFR, estimated
glomerular filtration rate; HF, heart failure; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide;
NYHA, New York Heart Association; SaO2, arterial oxygen saturation; SBP, systolic blood pressure; SD, standard deviation.
aValues in bold denote statistically significant differences.
bPerformed in only 485 individuals.
© 2017 The Authors
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Follow-up, days
92 92 92 9090 90 90 90 90 90 90 Patients with undetectable relaxin-2 (<1.5 pg/mL) at risk
Patients with detectable relaxin-2 (≥1.5 pg/mL) at risk
Patients at risk in Q1 (<10.2 pg/mL) 
Patients at risk in Q2 (10.2–23.5 pg/mL) 
Patients at risk in Q3 (23.6–52.5 pg/mL) 
Patients at risk in Q3 (>52.5 pg/mL) 
429 424 416 400407 405 402 396 395 392 390
0 3 6 9 12 15 18 21 24 27 30
107 106 101 101 98 98 97 96 96 96 96
106 106 103 100 99 98 98 98 98 98 98
107 105 104 103 103 102 102 100 100 97 95
107 107 106 103 103 102 101 100 99 99 99
Detectable (n = 430)
Crude HR = 1 (reference)
Undetectable (n = 92)
Crude HR = 0.231 (0.056–0.956)
Patients with detectable relaxin (n = 430)
Q3 Crude HR = 1.513 (0.619–3.302)
Q1 Crude HR = 1.423 (0.572–3.537)
Q2 Crude HR = 1.025 (0.285–2.731)
Q4 Crude HR = 1 (reference)
P = 0.660
Figure 1 Survival curves for mortality at 30 days: (A) in patients with detectable and unde-
tectable relaxin concentrations, and (B) according to relaxin concentration quartile (Q) in
patients with detectable levels. HR, hazard ratio.
vs. 9.1%; P = 0.026). The survival curve
analysis (Figure 1) showed a crude HR of 0.23
(95% CI 0.06–0.95; P = 0.043) in patients
with undetectable relaxin-2 concentrations,
which became 0.22 (95% CI 0.05–0.92; P =
0.038) after multivariate adjustment by sex,
heart valve disease, type of AHF and chronic
treatment with potassium-sparing diuretics.
Relaxin-2 concentrations in the 430
patients (82.4%) with detectable val-
ues did not follow a normal distribution
(Kolmogorov–Smirnov statistic 0.412, P
< 0.001) and reached a median of 30.0
pg/mL (IQR 15.2–70.5 pg/mL). Determina-
tions of concentrations were repeated in
80 patients, obtaining a Pearson correlation
coefficient of 0.74 (P < 0.001). No significant
differences in relaxin-2 concentrations were
found between patients who remained alive
(median: 30.9 pg/mL, IQR 15.8–74.7 pg/mL)
and those who had died (median: 30.9 pg/mL,
IQR 15.6–85.2 pg/mL) at 30 days (P = 0.89).
An analysis by quartiles (see supplementary
material online, Table S1) demonstrated that
patients with low relaxin-2 concentrations
[quartile (Q) 1 and Q2] more frequently
presented dyslipaemia (P = 0.007) and those
with high concentrations (Q3 and Q4) more
frequently received chronic treatment with
digoxin (P = 0.023). An analysis of 30-day
mortality by quartile showed no differences
(Figure 1), and neither were any interactions
with sex, age and type of AHF (first episode
vs. decompensation of chronic HF) observed
(P = 0.20, P = 0.23 and P = 0.63, respectively).
Analysis of correlations between relaxin-2
concentrations and other clinical and bio-
chemical parameters revealed a significant,
albeit weak (R2 = 0.018), correlation only
with haemoglobin values (P = 0.005) (Table 2).
Discussion
The RELAHF study achieved three main
findings: (i) relaxin-2 concentrations were not
detectable in a small proportion of patients
with AHF and this was associated with lower
30-day mortality; (ii) there was no relationship
between detectable relaxin-2 concentrations
and short-term patient outcome, and (iii)
relaxin-2 concentrations were not related to
NT-proBNP values or to other clinical or
analytical parameters (except haemoglobin).
We found 17.6% of patients with AHF
to have undetectable relaxin-2 blood con-
centrations. This incidence lies between the
7% described by Martinez-Solano et al.10
and the 25% reported by Pintalhao et al.7
It is likely that differences in the baseline
characteristics of the various study popula-
tions explain this variation. Remarkably, all of
these figures are very much lower than those
observed in healthy young people, in whom
relaxin-2 concentrations are undetectable
in 84% of men and 79% of women.3 This
suggests that relaxin-2 secretion may be a
compensatory factor in patients with HF and
may indicate partial failure of the remaining
homeostatic mechanisms induced by HF. The
lack of relaxin-2 detection may then identify
patients who, if all other clinical and bio-
chemical parameters associated with adverse
events are equal, have a lower probability of
short-term mortality.
In patients with detectable relaxin-2
concentrations, there was no relationship
between these concentrations and short-
term outcome. Few studies are available on
this relationship in patients with AHF and
the results are discordant, thereby mak-
ing comparison with our results difficult.
Fisher et al. found no relationship between
relaxin concentrations and 1-year mortality
in 87 patients with systolic dysfunction and
hospitalized for AHF during a clinical trial.6
Conversely, Pintalhao et al. reported a rela-
tionship between relaxin concentrations and
in-hospital mortality in 117 patients with
AHF.7 Finally, in 115 patients with chronic HF,
Xie et al. showed that relaxin concentrations
predicted the development of severe cardio-
vascular events within 180 days of hospital
© 2017 The Authors








































































































































































































































Table 2 Correlations between relaxin concentrations and other clinical and
analytical variables
Variable R R2 P-valuea
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age −0.039 0.002 0.42
SBP 0.058 0.003 0.24
Heart rate −0.063 0.004 0.20
LVEFb 0.002 0.000 0.98
Haemoglobin 0.134 0.018 0.005
eGFR 0.066 0.004 0.17
Sodium −0.035 0.001 0.47
Potassium 0.015 0.0002 0.74
Normalized troponins −0.016 0.000 0.75
NT-proBNP −0.064 0.004 0.19
eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-
brain natriuretic peptide; SBP, systolic blood pressure.
aValues in bold denote statistically significant differences.
bAvailable in only 166 individuals.
discharge (area under the curve: 0.816, 95%
CI 0.724–0.909).11 Mazurek et al.12 found
higher levels of relaxin in patients with pul-
monary hypertension. It is of note, however,
that the populations included in these studies
were very different from that of the current
RELAHF study. Indeed, the RELAHF study
enrolled a much larger sample of consec-
utively recruited patients (n = 522) with a
wider variety of clinical forms of AHF, ranging
from the mildest forms in patients discharged
from EDs without hospitalization to the most
severe forms in patients admitted to intensive
care units,9 which, in turn, led to marked
differences in baseline and clinical patient
characteristics between this and the previous
studies. One explanation for the lack of rela-
tionship between relaxin-2 concentration and
early death found in the present study may
refer to the expression of relaxin receptors.
Some studies have reported a reduction in
the expression of these receptors in failing
myocardiocytes.13 Consequently, an increase
in relaxin-2 secretion may result in insuffi-
cient response to this reduction in receptor
expression. Nonetheless, this hypothesis
must be investigated in future studies.
Finally, we failed to demonstrate correla-
tions between relaxin-2 concentrations and
several clinical and biochemical parameters,
with the exception of a significant, albeit weak
(R2 = 0.018), correlation with haemoglobin
values (P = 0.005). We have no explana-
tion for this finding. Haemoglobin values
are reduced in pregnant women as a result
of the physiological increase in volaemia, a
condition that, in part, reflects the adaptive
increase in relaxin-2 secretion. Of note, the
absence of a correlation between relaxin-2
and NT-proBNP concentrations in the
RELAHF study confirms previously published
results in smaller studies.6,7 This lack of rela-
tionship may be attributable to differences in
the release mechanisms and stimuli of each
of these proteins.14,15
Limitations
We did not register the time of HF signs
and symptoms evolution before ED consul-
tation, and neither did we measure levels
of testosterone or other sex hormones.
Echocardiographic evaluations were available
in 208 individuals (including 166 patients
with detectable relaxin-2 concentrations).
Although the method of relaxin-2 detection
was not standardized, we observed a good
correlation among determinations made in
duplicate. Data on the cause of death were
not available and therefore it was not possible
to establish whether secretion of relaxin-2
is exclusively associated with cardiovascular
mortality. Finally, as this was an exploratory
hypothesis-generating study, we did not
define, a priori, the sample size and therefore
results may include a beta error. In fact, the
statistical power for the differences in 30-day
mortality between the groups with unde-
tectable and detectable relaxin-2 was 66%.
Conclusions
The results of the RELAHF study suggest that
relaxin-2 may play a role in the pathophysiol-
ogy of AHF as the percentage of patients with
undetectable concentrations is lower than in
healthy people. Thus, patients not presenting
measurable concentrations of relaxin-2 in
blood may represent a subgroup with better
short-term prognosis, perhaps because they
are in a pathophysiologically early stage of
disease. Further studies are required to
confirm and expand these findings.
Supplementary Information
Additional Supporting Information may be
found in the online version of this article:
Table S1. Comparison of patients with
detectable relaxin-2 concentrations
according to relaxin-2 concentration
quartiles.
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